

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Pharmaron Beijing Co., Ltd.

康龍化成(北京)新藥技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3759)

**INSIDE INFORMATION ANNOUNCEMENT
REGARDING THE ESTIMATE FOR
INTERIM RESULTS OF 2025**

This announcement is made by Pharmaron Beijing Co., Ltd. (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The following is the estimate of the Company for the interim results of 2025. The financial data contained in this results estimate has not been audited and is, except for non-IFRSs (International Financial Reporting Standards) adjusted net profit attributable to owners of the parent or as otherwise indicated, prepared in accordance with the PRC Accounting Standards for Business Enterprises.

I. ESTIMATE FOR INTERIM RESULTS OF 2025

1. Period for the results estimate: January 1, 2025 to June 30, 2025
2. Results estimate

The estimated revenue, net profit attributable to owners of the parent excluding non-recurring gains or losses, and non-IFRSs adjusted net profit attributable to owners of the parent increased year-on-year, while the estimated net profit attributable to owners of the parent decreased year-on-year.

Item	Current reporting period	Same period last year
Revenue	Revenue: 6,333.0436 million – 6,501.1775 million Growth compared with the same period of last year: 13% – 16%	Revenue: 5,604.4634 million

Item	Current reporting period	Same period last year
Net profit attributable to owners of the parent	Profit: 679.1758 million – 712.5779 million Decrease compared with the same period of last year: 36% – 39%	Profit: 1,113.4030 million
Net profit attributable to owners of the parent excluding non-recurring gains or losses (<i>Note 2</i>)	Profit: 624.2831 million – 647.5772 million Growth compared with the same period of last year: 34% – 39%	Profit: 465.8829 million
Basic earnings per share	Profit: 0.3858/share – 0.4048/share	Profit: 0.6282/share
Non-IFRSs adjusted net profit attributable to owners of the parent (<i>Note 3</i>)	Profit: 731.6822 million – 766.1955 million Growth compared with the same period of last year: 6% – 11%	Profit: 690.2662 million

Note 1:

The “million” in this results estimate is in RMB million, unless otherwise defined.

Note 2:

According to the preliminary estimate by the Company, the non-recurring gains or losses attributable to owners of the parent for the interim period of 2025 would be in the range of approximately RMB60 million and RMB70 million, which mainly includes the government subsidies included in the current profit and loss, gains from changes in the fair value of other non-current financial assets and gains or losses related to the investment in low – and medium-risk bank wealth management products, etc.

Note 3:

To supplement the financial statements prepared by us, we use non-IFRSs adjusted net profit attributable to owners of the parent as an additional financial measure. We define non-IFRSs adjusted net profit attributable to owners of the parent as net profit before certain expenses/(gains): 1) share-based compensation expenses; 2) foreign exchange gains and losses and the income statement impact of the gains or losses of the corresponding foreign exchange hedging instruments; 3) realized and unrealized related gains or losses from equity investments; 4) Convertible Bonds related gains or losses; 5) Other incidental, non-cash or non-operating items.

The Company believes that the consideration of the non-IFRSs adjusted net profit attributable to owners of the parent by eliminating the impact of certain incidental, non-cash or non-operating items is useful for better understanding and assessing underlying business performance and operating trends for the Company’s management, shareholders and potential investors.

The non-IFRSs adjusted net profit attributable to owners of the parent is not an alternative to: (i) profit before tax or net profit (as determined in accordance with IFRSs) as a measure of our operating performance, (ii) cash flows from operating, investing and financing activities as a measure of our ability to satisfy our cash needs, or (iii) any other measures of performance or liquidity. In addition, the presentation of the non-IFRSs adjusted net profit attributable to owners of the parent is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRSs. Shareholders and potential investors should not view the non-IFRSs adjusted net profit attributable to owners of the parent on a stand-alone basis or as a substitute for results under the IFRSs, or as being comparable to results reported or forecasted by other companies.

II. COMMUNICATION STATUS WITH THE ACCOUNTING FIRM

The results estimate has not been audited or pre-audited by the certified public accountants.

III. REASONS FOR CHANGES IN RESULTS

1. Impact of principal business

The Company remained steadfast in implementing its core strategy of developing an end-to-end, fully integrated and multiple modalities-capable services platform with global footprints. Guided by customer demand, the Company further deepened its global footprint while strengthening its technological capabilities. In the first half of 2025, the Company's revenue is estimated to increase by 13% to 16% year-on-year; the net profit attributable to owners of the parent excluding non-recurring gains or losses increased by 34% to 39% year-on-year; and the non-IFRSs adjusted net profit attributable to owners of the parent increased by 6% to 11% year-on-year.

At the midpoint of the estimated results, in the second quarter of 2025, the Company's revenue increased by 13.11% year-on-year; the net profit attributable to owners of the parent excluding non-recurring gains or losses increased by 23.33% year-on-year; and the non-IFRSs adjusted net profit attributable to owners of the parent increased by 13.67% year-on-year.

2. Impact of non-recurring gains or losses

As mentioned above, the non-recurring gains or losses attributable to owners of the parent during the reporting period amounted to approximately RMB60 million to RMB70 million. The non-recurring gains or losses attributable to owners of the parent in the same period of last year were RMB647.5201 million mainly due to the disposal of equity in PROTEOLOGIX, INC.. The non-recurring gains or losses decreased by approximately RMB577.5201 million to RMB587.5201 million.

Under the circumstances where the main business continues to improve, mainly due to the decrease in non-recurring gains and losses, the net profit attributable to owners of the parent decreased by 36% to 39% as compared with the same period of the last year.

IV. ADDITIONAL INFORMATION

1. The estimated data of the results disclosed in this announcement is only a preliminary estimate made by the finance department of the Company and has not been audited or pre-audited by the certified public accountants.
2. Details of the Company's interim results of 2025 prepared under the PRC Accounting Standards for Business Enterprises or IFRSs will be disclosed in the interim report 2025 to be published by the Company on the Shenzhen Stock Exchange or The Stock Exchange of Hong Kong Limited, respectively. Investors are advised to exercise caution and pay attention to investment risks involved.

By order of the Board
Pharmaron Beijing Co., Ltd.
Dr. Lou Boliang
Chairman

Beijing, the PRC
July 15, 2025

As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Li Jiaqing and Ms. Wan Xuan as non-executive Directors; Ms. Li Lihua, Mr. Tsang Kwan Hung Benson and Mr. Yu Jian as independent non-executive Directors.